Back

High Drug-Loading Rucaparib-FdUMP Nanocarriers for Colorectal Cancer Combination Therapy

Weber, A. E.; Ritschel, C.; Feldmann, C.; Kossatz, S.

2026-05-28 cancer biology
10.64898/2026.05.25.727099 bioRxiv
Show abstract

Combination chemotherapy remains the standard of care for advanced colorectal cancer, yet the clinical benefit is limited by off-target toxicity and insufficient tumor drug exposure. Co-administration of 5-fluorouracil (5-FU) with poly(ADP-ribose) polymerase (PARP) inhibitors such as rucaparib (RUC) can potentiate 5-FU-induced DNA damage by suppressing DNA repair but achieving robust co-delivery at defined ratios and high payload remains challenging. Here, we report high drug-loading core@shell nanocarriers (RUC@[ZrO][FdUMP]) that co-deliver RUC and the active 5-FU metabolite fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP). Nanocarriers were synthesized via a solvent-antisolvent approach to form a tocopherol phosphate (TocP)-stabilized RUC core followed by the growth of an amorphous [ZrO][FdUMP] shell, yielding an overall drug load of 59 wt%. Dual fluorescence (shell incorporation of DUT647 and intrinsic RUC emission) enabled quantitative tracking and revealed rapid uptake in HCT116 and HT29 colorectal cancer cells and tumor accumulation in a subcutaneous HT29 xenograft. In vitro, RUC@[ZrO][FdUMP] showed cytotoxicity comparable to the free-drug combination, induced S-phase arrest, and increased {gamma}H2AX foci, consistent with replication stress and DNA double-strand break formation. Drug-drug interaction analysis demonstrated synergistic activity of the RUC/FdUMP pair in colorectal cancer cells. Together, these results establish RUC@[ZrO][FdUMP] as a high-payload nanocarrier platform for co-delivering synergistic PARP inhibitor/fluoropyrimidine combinations, supporting further development and in vivo evaluation of this co-delivery strategy for colorectal cancer therapy. TOC Graphics O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=50 SRC="FIGDIR/small/727099v1_ufig1.gif" ALT="Figure 1"> View larger version (15K): org.highwire.dtl.DTLVardef@dd9ad6org.highwire.dtl.DTLVardef@e07aecorg.highwire.dtl.DTLVardef@1a63505org.highwire.dtl.DTLVardef@e30d58_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.